Anti-RANKL antibody [12A668] - BSA and Azide free (ab45039)
![Western blot - Anti-RANKL antibody [12A668] - BSA and Azide free (ab45039)](https://www.abcam.com/ps/products/45/ab45039/Images/ab45039-57170-anti-rankl-antibody-12a668-western-blot.jpg "Western blot - Anti-RANKL antibody [12A668] - BSA and Azide free (ab45039)")
Key features and details
- Mouse monoclonal [12A668] to RANKL - BSA and Azide free
- Suitable for: ICC/IF, WB, IHC-P
- Reacts with: Human
- Isotype: IgG1
Overview
-
Product name
Anti-RANKL antibody [12A668] - BSA and Azide free
See all RANKL primary antibodies -
Description
Mouse monoclonal [12A668] to RANKL - BSA and Azide free -
Host species
Mouse -
Tested applications
Suitable for: ICC/IF, WB, IHC-Pmore details
Unsuitable for: Flow Cyt -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant full length protein corresponding to Mouse RANKL aa 1-317.
Database link: O14788 -
Positive control
- IHC-P: Human lymph node and liver tissue. ICC/IF: HeLa (human epithelial cell line from cervix adenocarcinoma) cells. WB: Human lymph node lysate.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. -
Storage buffer
pH: 7.40
Constituent: PBS -
Carrier free
Yes -
Concentration information loading... -
Purity
Protein G purified -
Clonality
Monoclonal -
Clone number
12A668 -
Isotype
IgG1 -
Light chain type
kappa -
Research areas
Associated products
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab45039 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| ICC/IF |
Use a concentration of 10 µg/ml.
|
|
| WB | (1) |
Use a concentration of 1 - 2 µg/ml. Detects a band of approximately 35 kDa (predicted molecular weight: 35 kDa).
|
| IHC-P | (1) |
Use a concentration of 1 - 5 µg/ml.
|
| Notes |
|---|
|
ICC/IF
Use a concentration of 10 µg/ml. |
|
WB
Use a concentration of 1 - 2 µg/ml. Detects a band of approximately 35 kDa (predicted molecular weight: 35 kDa). |
|
IHC-P
Use a concentration of 1 - 5 µg/ml. |
Target
-
Function
Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy. -
Tissue specificity
Highest in the peripheral lymph nodes, weak in spleen, peripheral blood Leukocytes, bone marrow, heart, placenta, skeletal muscle, stomach and thyroid. -
Involvement in disease
Defects in TNFSF11 are the cause of osteopetrosis autosomal recessive type 2 (OPTB2) [MIM:259710]; also known as osteoclast-poor osteopetrosis. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. The disorder occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Autosomal recessive osteopetrosis is usually associated with normal or elevated amount of non-functional osteoclasts. OPTB2 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development. -
Sequence similarities
Belongs to the tumor necrosis factor family. -
Post-translational
modificationsThe soluble form of isoform 1 derives from the membrane form by proteolytic processing (By similarity). The cleavage may be catalyzed by ADAM17. -
Cellular localization
Cytoplasm; Secreted and Cell membrane. - Information by UniProt
-
Database links
- Entrez Gene: 8600 Human
- Omim: 602642 Human
- SwissProt: O14788 Human
- Unigene: 333791 Human
-
Alternative names
- CD254 antibody
- hRANKL2 antibody
- ODF antibody
see all
Images
-
Western blot - Anti-RANKL antibody [12A668] - BSA and Azide free (ab45039)Anti-RANKL antibody [12A668] - BSA and Azide free (ab45039) at 2 µg + transfected cell lysate
Predicted band size: 35 kDa
Observed band size: 35 kDa -
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-RANKL antibody [12A668] - BSA and Azide free (ab45039)](https://www.abcam.com/ps/products/45/ab45039/Images/ab45039-212683-anti-rankl-antibody-12a668-immunohistochemistry.jpg)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-RANKL antibody [12A668] - BSA and Azide free (ab45039)Paraffin embedded human lymph node tissue stained for RANKL with ab45039 at 5 µg/ml.
-
![Immunocytochemistry/ Immunofluorescence - Anti-RANKL antibody [12A668] - BSA and Azide free (ab45039)](https://www.abcam.com/ps/products/45/ab45039/Images/ab45039-57169-anti-rankl-antibody-12a668-immunofluorescence.jpg)
Immunocytochemistry/ Immunofluorescence - Anti-RANKL antibody [12A668] - BSA and Azide free (ab45039)ICC/IF image of ab45039 stained HeLa cells. The cells were 4% formaldehyde fixed (10 minutes) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1 hour to permeabilize the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab45039, 10 µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-mouse IgG (H+L) used at a 1/1000 dilution for 1 hour. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1 hour. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43 µM.
-
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-RANKL antibody [12A668] - BSA and Azide free (ab45039)](https://www.abcam.com/ps/products/45/ab45039/Images/ab45039-212682-anti-rankl-antibody-12a668-immunohistochemistry.jpg)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-RANKL antibody [12A668] - BSA and Azide free (ab45039)Paraffin embedded human liver tissue stained for RANKL with ab45039 at a 1/500 dilution. Peroxidase-conjugate and DAB chromogen. A 2 hour incubation at RT was used.
-
![Western blot - Anti-RANKL antibody [12A668] - BSA and Azide free (ab45039)](https://www.abcam.com/ps/products/45/ab45039/Images/ab45039-282855-anti-rankl-antibody-12a668-western-blot.jpg)
Western blot - Anti-RANKL antibody [12A668] - BSA and Azide free (ab45039)Anti-RANKL antibody [12A668] - BSA and Azide free (ab45039) at 0.5 µg/ml + human lymph node lysate in RIPA buffer at 35 µg
Predicted band size: 35 kDa
Additional bands at: 28 kDa (possible isoform)Band detected at ~35kDa and ~28kDa. (Expected MW of 35.5kDa according to NP_003692.1 and of 27.7kDa according to NP_143026.1)
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (55)
ab45039 has been referenced in 55 publications.
- Wang Y et al. Radiation induces primary osteocyte senescence phenotype and affects osteoclastogenesis in vitro. Int J Mol Med 47:N/A (2021). PubMed: 33693957
- Zhao L et al. Catalpol Protects Against High Glucose-Induced Bone Loss by Regulating Osteoblast Function. Front Pharmacol 12:626621 (2021). PubMed: 33776769
- Zhang B et al. Effects of WNT1 c.110?T>C and c.505G>T mutations on osteoblast differentiation via the WNT1/ß-catenin signaling pathway. J Orthop Surg Res 16:359 (2021). PubMed: 34078411
- Sheng H et al. Combined Pharmacotherapy with Alendronate and Desferoxamine Regulate the Bone Resorption and Bone Regeneration for Preventing Glucocorticoids-Induced Osteonecrosis of the Femoral Head. Biomed Res Int 2020:3120458 (2020). PubMed: 33029500
- Zhou Y et al. Melatonin up-regulates bone marrow mesenchymal stem cells osteogenic action but suppresses their mediated osteoclastogenesis via MT2 -inactivated NF-?B pathway. Br J Pharmacol 177:2106-2122 (2020). PubMed: 31900938